Latest Cholestasis Stories
LEXINGTON, Massachusetts, April 9, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the 13-week Phase 2 IMAGO trial of its investigational compound
FDA approves oral therapy as a first-in-class treatment BALTIMORE, March 17, 2015 /PRNewswire-USNewswire/ -- Asklepion Pharmaceuticals, LLC. today announced that the U.S.
GOTHENBURG, Sweden, February 5, 2015 /PRNewswire/ -- Albireo today announced initiation of a phase II trial with A4250, the company's lead compound for cholestatic liver
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
CAMEO Phase 2 Clinical Trial of LUM001 Now Enrolling Adults with Primary Sclerosing Cholangitis SAN DIEGO, May 9, 2014 /PRNewswire/ --
CINCINNATI, May 3, 2014 /PRNewswire-USNewswire/ -- A multi-center study concludes that treating infants with high doses of steroids fails to improve medical outcomes in the end-stage pediatric
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements.
- A hairdresser.